Mark Windfeld-Hansen

Cooley advised Veritone, a company building human-centered enterprise artificial intelligence (AI) solutions, on the sale of its media agency, Veritone One, to Insignia Capital Group.

Cooley advised RTZ Systems, an information technology and services company, on its acquisition by CollabriOS Health, a new entity formed by Assured Healthcare Partners that brings together a suite of integrated technology infrastructure, including electronic health records, third-party administrator financial services, and care coordination solutions designed to help Programs of All-Inclusive Care for the Elderly (PACE) optimize workflows, streamline business processes and enhance overall center operations.

Cooley advised Ionis Pharmaceuticals (Nasdaq: IONS), a biotechnology research company inventing medicines that bring better futures to people with serious diseases, on its $500.3 million underwritten public offering of common stock.

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised DEFCON AI, an insights company that’s building a next-generation modeling, simulation and analysis tool set for the modern military environment, on its $44 million in Seed financing.